Ongoing Clinical Development Program Represents Largest and Longest Development Program for any Gene Therapy in Hemophilia A, Demonstrates Commitment to Advancing Care for People with Hemophilia A
SAN RAFAEL, Calif., May 5, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)
"We're pleased to provide updated data on durability of effect in patients treated over two years ago, on molecular contributors to variability, on hepatotoxicity and the role of immunosuppression, on the potential for integration-related oncogenicity, and on health-related quality of life. We continue to learn about the potential for investigational valoctocogene roxaparvovec to transform lives and the optimal way to manage patients through their journey," said Hank Fuchs, M.D., President of Worldwide Research and Development at BioMarin. "We are progressing our regulatory efforts with the intent to deliver a therapy that may represent an important and valuable treatment choice for patients with severe Hemophilia A, as no presently available treatment offers such freedom from prophylaxis and reduced bleeding frequency at the same time."
"BioMarin is generating valuable data about investigational valoctocogene roxaparvovec that potentially could enable shared decision making between physicians and patients on what is the best therapy in each personal situation," said Professor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre at the Goethe University Hospital in Frankfurt/Main, Germany.
Presentation of data at WFH follows positive two-year results from the ongoing, global phase 3 GENEr8-1 study of valoctocogene roxaparvovec presented at a medical meeting earlier in the year, as well as publication of one-year results from the pivotal clinical trial in the New England Journal of Medicine in March 2022.
Story continues
BioMarin's presentations at WFH include:
Platform Presentations
Immune suppression following gene therapy in HemophiliaProfessor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main, GermanyMonday, May 9, 2022, 1:30 -2:30 PM ET
Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for valoctocogene roxaparvovec vector insertion in altering cell growthKevin Eggan, Group Vice President, Head of Research and Early Development / BioMarinMonday, May 9, 2022, 1:30 -2:30 PM ET
Health-related quality of life over 2 years following valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from GENEr8-1Dr. Amy Dunn, Director of Pediatric Hematology, Nationwide Children's Hospital, Columbus, OhioTuesday, May 10, 2022, 1:30-2:30 PM ET
Human liver biopsy analysis showed interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A Sylvia Fong, Head of Hematology Research, BioMarinWednesday, May 11, 2022, 1:30 -2:30 PM ET
Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-medicated gene therapy for hemophilia A Brian Long, Principal Scientist, Clinical Immunology, BioMarinWednesday, May 11, 2022, 4-5 PM ET
Poster Presentation
Use of immunosuppressives in patients with hemophilia receiving gene therapy: Evidence generation using a mixed-methods approach Professor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main, Germany
BioMarin-Sponsored Symposia
Gene Therapy Clinical Trial Patient Journey: A Look Into Shared Decision MakingMonday, May 9, 12:15 1:15 PM ET
About Hemophilia A
People living with hemophilia A lack sufficient functioning Factor VIII protein to help their blood clot and are at risk for painful and/or potentially life-threatening bleeds from even modest injuries. Additionally, people with the most severe form of hemophilia A (FVIII levels <1%) often experience painful, spontaneous bleeds into their muscles or joints. Individuals with the most severe form of hemophilia A make up approximately 50 percent of the hemophilia A population. People with hemophilia A with moderate (FVIII 1-5%) or mild (FVIII 5-40%) disease show a much-reduced propensity to bleed. The standard of care for individuals with severe hemophilia A is a prophylactic regimen of replacement Factor VIII infusions administered intravenously up to two to three times per week or 100 to 150 infusions per year. Despite these regimens, many people continue to experience breakthrough bleeds, resulting in progressive and debilitating joint damage, which can have a major impact on their quality of life.
Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have Hemophilia A.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. For additional information, please visit http://www.biomarin.com.
Forward Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including without limitation, statements about: the data presented at WFH, including the five platform presentations, one poster, and one BioMarin sponsored symposia, the development of BioMarin's valoctocogene roxaparvovec program generally, the impact of valoctocogene roxaparvovec gene therapy for treating patients with severe hemophilia A and the potential to transform the lives of these patients and the ongoing clinical programs generally. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of valoctocogene roxaparvovec, including final analysis of the above data and additional data from the continuation of these trials and the entire development program, including further assessment of safety events, any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the FDA, the EMA and other regulatory authorities; the content and timing of decisions by local and central ethics committees regarding the clinical trials; our ability to successfully manufacture valoctocogene roxaparvovec; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin is a registered trademark of BioMarin Pharmaceutical Inc.
Contacts:
Investors
Media
Traci McCarty
Debra Charlesworth
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558
(415) 455-7451
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-findings-from-ongoing-studies-of-valoctocogene-roxaparvovec-investigational-gene-therapy-at-the-world-federation-of-hemophilia-2022-world-congress-may-8-11-2022-including-five-platform-presentations-301540667.html
SOURCE BioMarin Pharmaceutical Inc.
- VA research will bring precision medicine to mental health - VAntage Point - VAntage Point Blog - June 11th, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UC develops new lung cancer treatment | University Of Cincinnati - University of Cincinnati - June 11th, 2022
- CTGT transactions: Beware of ripples in the safe harbor - JD Supra - June 11th, 2022
- Startup offers genetic testing that promises to predict healthiest embryo - WHYY - June 11th, 2022
- WHRY Funds Studies on Sex Differences in Treating Gastrointestinal Cancers, Bone Health in Transgender Youth, and the Greater Risk for Alzheimer's... - June 11th, 2022
- NIH awards USC more than $16 million for research on vascular dysfunction and Alzheimer's disease | Keck School of Medicine of USC - University of... - June 11th, 2022
- Effect of Metformin on Glycemic Control | DMSO - Dove Medical Press - June 11th, 2022
- Overcoming the Challenges of Cell and Gene Therapy Facilities - Genetic Engineering & Biotechnology News - June 3rd, 2022
- Organoids test gene therapies for Pitt-Hopkins syndrome - Spectrum - June 3rd, 2022
- Gene Therapy Successfully Treats Spinal Cord Injuries Without Side Effects - SciTechDaily - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - EurekAlert - June 3rd, 2022
- Labcorp Expands Access to Comprehensive Genomic Testing Through New Lung Cancer Program - Business Wire - June 3rd, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 3rd, 2022
- Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision... - June 3rd, 2022
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA)... - June 3rd, 2022
- Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer - DocWire News - June 3rd, 2022
- Winship receives $11 million grant from the National Cancer Institute to improve immunotherapy for lung cancer - EurekAlert - June 3rd, 2022
- Gene Editing Service Market Report 2022-2028 | Keyplayers- Caribou Biosciences, CRISPR Therapeutics, Merck KGa, Editas Medicine The Greater... - June 3rd, 2022
- Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO -... - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - University of Rochester - May 28th, 2022
- Welsh wins 2022 Shaw Prize in Life Sciences and Medicine | Carver College of Medicine - The University of Iowa - May 28th, 2022
- Episode 2: Are We Any Closer to Intestinal Gene Therapy in Crohn's Disease? - Medscape - May 28th, 2022
- Middle East Team Calls for Local Availability of Rapid WGS to Diagnose Severely Ill Infants - GenomeWeb - May 28th, 2022
- The Efficacy of Japanese Herbal Kampo Medicine as an Acute and Prophylactic Medication to Treat Chronic Daily Headache and Medication Overuse... - May 28th, 2022
- Breast cancer in man unexpectedly diagnosed after chest pain - The Columbus Dispatch - May 28th, 2022
- While the fetal clock develops, moms behaviour tells the time - The Daily Star - May 28th, 2022
- Foundation Medicine and Collaborators to Share More Than 20 Abstracts Featuring New Data at the 2022 American Society of Clinical Oncology Annual... - May 28th, 2022
- Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy - BioSpace - May 28th, 2022
- Project SG100K: DNA of 100000 Singaporeans to be mapped to identify new ways to prevent diseases - The Straits Times - May 28th, 2022
- Study reveals potential target for treatment of diseases associated with mitochondrial DNA mutations - EurekAlert - May 28th, 2022
- Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene... - May 28th, 2022
- INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual... - May 28th, 2022
- Outlook on the Single-use Technologies for Biopharmaceuticals Global Market to 2026 - Increasing Demand for Personalized Medicine is Driving Growth -... - May 28th, 2022
- Bostons Seaport gets new cell and gene therapy research center, more to come - Boston Herald - May 17th, 2022
- The CasPlus Gene Editing Platform Technology can Correct Mutations Associated with Duchenne's Muscular Dystrophy and Cystic Fibrosis with High... - May 17th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 17th, 2022
- Will we be able to check cholesterol using gene editing technology or will it be too dangerous and costly to even try? - L'Observateur - L'Observateur - May 17th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 17th, 2022
- Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics - GlobeNewswire - May 17th, 2022
- This Gene Mutation Breaks the Immune System. Why Has It Survived? - WIRED - May 17th, 2022
- BRCA Experts Rally to Research DNA Repair for Better Breast, Ovarian and Other Cancer Treatments - Yale School of Medicine - May 17th, 2022
- AskBio to Present 11 Abstracts at Upcoming American Society of Gene and Cell Therapy's 25th Annual Meeting - PR Newswire - May 17th, 2022
- Protein linked to intellectual disability has complex role Washington University School of Medicine in St. Louis - Washington University School of... - May 17th, 2022
- CU School of Medicine Research Defines the Role of HDAC6 in Regulating Heart Stiffness - University of Colorado Anschutz Medical Campus - May 17th, 2022
- Emendo Biotherapeutics' next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related... - May 17th, 2022
- Latest Human Cells Atlas reveals more of the unknown world inside our bodies - EL PAS in English - May 17th, 2022
- Middle-East precision medicine market was estimated to be at $3,942.6 million in 2021, which is expected to grow with a CAGR of 7.37% and reach... - May 17th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting -... - May 6th, 2022
- Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American... - May 6th, 2022
- Top 12 emerging gene and cell therapy technologies likely to impact patient care announced in annual Disruptive Dozen from Mass General Brigham -... - May 6th, 2022
- Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results - GlobeNewswire - May 6th, 2022
- Athenex, Texas Childrens Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for... - May 6th, 2022
- The gene-edited pig heart given to a dying patient was infected with a pig virus - MIT Technology Review - May 6th, 2022
- WMIF panel: How cell and gene therapy can overcome limitations of CAR T - MedCity News - May 6th, 2022
- Promising results shown in the treatment of growth-hormone resistant dwarfism - EurekAlert - May 6th, 2022
- New treatment for infants with weakened immune systems - Sciworthy - May 6th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 6th, 2022
- Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases -... - May 6th, 2022
- A very specific kind of brain cell dies off in people with Parkinson's - Science News Magazine - May 6th, 2022
- Gene Editing Tools Market by 2029 Thermofisher Scientific, CRISPR Therapeutics, Editas Medicine Queen Anne and Mangolia News - Queen Anne and... - May 6th, 2022
- Sleep deprivation may increase the risk of eye disease - Medical News Today - May 6th, 2022
- Parkinson's Foundation Announces Major Expansion of PD GENEration Study, Increasing Access to Genetic Testing and Counseling Across the US - PR... - May 3rd, 2022
- Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease - Yahoo Finance - May 3rd, 2022
- Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy... - May 3rd, 2022
- Ting, Baric Elected to American Academy of Arts & Sciences | Newsroom - UNC Health and UNC School of Medicine - May 3rd, 2022
- Global Genes and the Orphan Disease Center of the University of Pennsylvania Host 7th Annual RARE Drug Development Symposium - Yahoo Finance - May 3rd, 2022
- May 2022: Nuclear condensates' role in gene regulation, disease focus of talk - Environmental Factor Newsletter - May 3rd, 2022
- Race, ethnicity, and ancestry have no standard definitions in medicine - Sciworthy - May 3rd, 2022
- Folk Medicine Discovery Could Lead to Better Heart Attack Outcomes - The Roanoke Star - May 3rd, 2022
- Genetic breakthrough could be the key that unlocks lupus - Cosmos - May 3rd, 2022
- ASGCT Partners with PlatformQ Health to Bring Impactful, Timely Gene and Cell Therapy Digital Education to Providers and Patients - PR Web - May 3rd, 2022
- Genomics technology and the future of food security and human health - TheCable - May 3rd, 2022
- Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting - GlobeNewswire - May 3rd, 2022
- ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University - GlobeNewswire - May 3rd, 2022
- GAO Makes MACPAC Appointments and Reappointments | US GAO - Government Accountability Office - May 3rd, 2022
- Optogenetic Gene Therapy Company Ray Therapeutics Awarded $4 Million Grant - Pulse 2.0 - May 3rd, 2022
- Does autism begin in the womb? - EurekAlert - May 3rd, 2022
- Molecular Treatment Is Able to Control Brain Metastasis of Different Tumors - OncLive - May 3rd, 2022